Lanoxin (Digoxin)

Digoxin inhibits the Na⁺/K⁺‑ATPase pump on heart muscle cells, leading to increased intracellular sodium. This change reduces the sodium‑calcium exchanger activity, causing calcium buildup that strengthens heart contractions. Additionally, digoxin enhances vagal tone, slowing conduction through the atrioventricular node and helping to regulate abnormal heart rhythms.

The specific dose of Lanoxin is individualized by the prescribing clinician based on the patient’s age, weight, renal function, electrolyte status and therapeutic response. Dosage adjustments are made after evaluating serum digoxin concentrations and clinical effect, so the exact regimen varies from case to case.

Lanoxin is classified as Pregnancy Category C, meaning it should be used only if the potential benefit justifies any potential risk to the fetus. Limited data exist for breastfeeding, and the drug may pass into breast milk. Healthcare providers should weigh risks and discuss alternatives when treating pregnant or nursing patients.

To place an order, submit an enquiry on the Lanoxin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Unlike many anti‑arrhythmics that primarily block ion channels, Lanoxin is a cardiac glycoside that increases contractility and slows AV‑node conduction. Its unique mechanism offers benefits in heart failure where inotropic support is needed, but it requires careful monitoring for toxicity, a consideration less prominent with many newer class III agents.

Lanoxin should be stored at controlled room temperature, below 25 °C, in its original container. The packaging protects the product from moisture and light, helping maintain potency and sterility until the point of use.

Lanoxin is supplied as an intravenous solution and is administered by a healthcare professional directly into a vein. The injection is given over a short period, typically as a loading dose followed by maintenance dosing, according to the prescriber’s instructions and the patient’s clinical status.

The most serious risks include digoxin toxicity, which can manifest as life‑threatening cardiac arrhythmias, severe bradycardia, heart block, and hyperkalemia. Early signs such as visual disturbances, nausea, and confusion should prompt immediate medical evaluation to prevent progression to critical events.

Lanoxin is contraindicated in patients with ventricular arrhythmias, advanced atrioventricular block without a pacemaker, and those with known hypersensitivity to digoxin or other cardiac glycosides. Caution is also advised for individuals with severe renal impairment, uncontrolled electrolyte abnormalities, or pregnancy unless benefits outweigh risks.